What does PD-L1 positive or negative mean?

被引:263
|
作者
Ribas, Antoni [1 ,2 ]
Hu-Lieskovan, Siwen [1 ,2 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, JCCC, Los Angeles, CA 90095 USA
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 2016年 / 213卷 / 13期
基金
美国国家卫生研究院;
关键词
CELL LUNG-CANCER; ADAPTIVE IMMUNE RESISTANCE; ADVANCED MELANOMA; UNTREATED MELANOMA; CLINICAL ACTIVITY; HODGKIN LYMPHOMA; OPEN-LABEL; EXPRESSION; BLOCKADE; NIVOLUMAB;
D O I
10.1084/jem.20161462
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti-PD-1/L1 antibodies. The expression of PD-L1 is regulated in different ways, which leads to a different significance of its presence or absence. PD-L1 positivity may be a result of genetic events leading to constitutive PD-L1 expression on cancer cells or inducible PD-L1 expression on cancer cells and noncancer cells in response to a T cell infiltrate. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response. Finally, a tumor that is unable to express PD-L1 because of a genetic event will always be negative for PD-L1 on cancer cells.
引用
收藏
页码:2835 / 2840
页数:6
相关论文
共 50 条
  • [41] Relevance of host and tumor PD-L1 in PD-L1 pathway blockade
    Kryczek, Ilona
    Lin, Heng
    Wei, Shuang
    Green, Michael
    Zou, Weiping
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [42] PD-L1 blockade efficacy relies on host cell PD-L1
    Brownell, I.
    Udey, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : 1000 - 1000
  • [43] PD-L1 Expression in Triple-Negative Breast Cancer
    Mittendorf, Elizabeth A.
    Philips, Anne V.
    Meric-Bernstam, Funda
    Qiao, Na
    Wu, Yun
    Harrington, Susan
    Su, Xiaoping
    Wang, Ying
    Gonzalez-Angulo, Ana M.
    Akcakanat, Argun
    Chawla, Akhil
    Curran, Michael
    Hwu, Patrick
    Sharma, Padmanee
    Litton, Jennifer K.
    Molldrem, Jeffrey J.
    Alatrash, Gheath
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (04) : 361 - 370
  • [44] PD-L1 status of triple negative breast cancer in Russia
    Frank, G.
    Kuznetsova, O.
    Zavalishina, L.
    Andreeva, Y.
    Moskvina, L.
    Karaseva, V.
    Tjulandin, S.
    VIRCHOWS ARCHIV, 2020, 477 : S232 - S232
  • [45] PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma
    Otsuka, A.
    Honda, Y.
    Ono, S.
    Kabashima, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S49 - S49
  • [46] Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas
    Huang, Richard S. P.
    Haberberger, James
    Harries, Lukas
    Severson, Eric
    Duncan, Daniel L.
    Ferguson, N. Lynn
    Hemmerich, Amanda
    Edgerly, Claire
    Murugesan, Karthikeyan
    Xiao, Jinpeng
    McEwan, Deborah
    Holmes, Oliver
    Hiemenz, Matthew
    Venstrom, Jeffrey
    Elvin, Julia A.
    Creeden, James
    Lin, Douglas I.
    Ross, Jeffrey S.
    Ramkissoon, Shakti H.
    ONCOLOGIST, 2021, 26 (05): : 375 - 382
  • [47] The prognostic value of PD-L1/PD-1 expression and PD-L1 gene copy number on/in tumor and immune cells in triple negative breast cancer
    Seitz, S.
    Brockhoff, G.
    Weber, F.
    Klinkhammer-Schalke, M.
    Zeman, F.
    Ugocsai, P.
    Ortmann, O.
    Wege, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 4 - 4
  • [48] PD-L1 expression in endometrial carcinomas: which tumours are more likely to be PD-L1-positive?
    Amarin, J. Z.
    Mansour, R.
    Al-Ghnimat, S.
    Lataifeh, I.
    Jaradat, I.
    Abdeen, G.
    Otay, L.
    Shatnawi, Q.
    Abu Sheikha, A.
    Dayyat, A.
    Abuhijla, F.
    El Khaldi, M.
    Al-Hussaini, M.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S31 - S31
  • [49] PD1, PD-L1 and PD-L2 mRNA Expression in triple-negative Breast Cancer
    Schueler, K.
    Bethmann, D.
    Staege, M.
    Kantelhardt, J. E.
    Thomssen, C.
    Vetter, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (06) : E24 - E24
  • [50] Immune profiling of malignant pleural mesothelioma by flow cytometry identifies distinct T-cell activation and exhaustion phenotypes in PD-L1 positive versus PD-L1 negative tumors
    Awad, Mark M.
    Bittinger, Mark A.
    Jones, Robert E.
    Liao, Xioayun
    Kulkarni, Meghana
    Keogh, Lauren
    Koyama, Shohei
    Almonte, Christina G.
    Santos, Abigail A.
    English, Jessie E.
    Barlow, Julianne
    Richards, William G.
    Hammerman, Peter S.
    Rodig, Scott J.
    Bueno, Raphael
    Wong, Kwok-Kin
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S17 - S17